Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lifestyle Modification and Metformin Use in the Treatment of HIV

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Steven K. Grinspoon, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00399360
First received: November 13, 2006
Last updated: September 13, 2012
Last verified: September 2012

November 13, 2006
September 13, 2012
December 2006
June 2011   (final data collection date for primary outcome measure)
  • Carotid Intima Media Thickness [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Carotid intima media thickness imaging of the common carotid artery was conducted using a high-resolution 7.5-MHz phased-array transducer (SONOS 2000/2500. The change of the carotid intima media thickness measurement between baseline and 12 months is reported.
  • Waist Circumference [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Iliac waist circumference measurements were obtained using an inelastic tape measure. All measurements were obtained in triplicate, with the patient undressed, and then averaged. The change of the waist circumference measurement between baseline and 12 months is reported.
  • High Density Lipoprotein (HDL) [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    High density lipoprotein (HDL) was determined after an overnight fast. The change in HDL between baseline and 12 months is reported.
  • Glucose [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Glucose level was determined after an overnight fast. The change in glucose between baseline and 12 months is reported.
  • Systolic Blood Pressure [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Systolic blood pressure was measured after 5 minutes rest. The in systolic blood pressure between baseline and 12 months is reported.
  • Coronary Artery Calcium Score [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Computed tomography (CT) imaging was performed using a SOMATOM Sensation (Siemens Medical Solutions, Forcheim, Germany) 64-slice CT scanner. Agatston calcium score was calculated using CT images. The total Agatston score is calculated by summing up the scores of the individual calcifications in all slices of the CT scan. An absolute Agatston score of less than 10 indicates minimal overall atherosclerosis (plaques) in the coronary arteries. The change in the coronary artery calcium score between baseline and 12 months is reported.
Carotid Intima media thickness
Complete list of historical versions of study NCT00399360 on ClinicalTrials.gov Archive Site
  • C-reactive Protein [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    High sensitivity C-reactive protein was determined by R&D Systems (Minneapolis, MN) kit. The change in C-reactive protein between baseline and 12 months is reported.
  • Abdominal Visceral Adiposity [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Abdominal visceral adipose area was assess by magnetic resonance imaging at the lvel of the L4 pedicle. The change in abdominal visceral adiposity between baseline and 12 months is reported.
  • Cardiorespiratory Fitness [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    A submaximal exercise stress test was conducted on a cycle ergometer to measure endurance. Subjects cycled between 50-60 revolutions per minute and the workload was progressively increased in increments of 50 watts in stages lasting 3 minutes. Once subjects became fatigued or reached their submaximal heart rate (220-age x 85), the test was stopped and separate readings of heart rate and blood pressure were measured at 1, 3, and 5 min of recovery. Weight-adjusted maximum oxygen consumption (VO2max; ml/kg per minute) was determined. The change in cardiorespiratory fitness between baseline and 12 months is reported.
  • Intramyocellular Lipid [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Intramyocellular lipid (IMCL) of the tibialis anterior was determined using 1H-magnetic resonance spectroscopy (Siemens, Munich, Germany). The change in the intramyocellular lipid measurement between baseline and 12 months is reported.
  • Waist circumference
  • Blood pressure
  • Lipid levels
  • Glucose
  • Inflammatory markers
  • visceral adiposity
  • cardiorespiratory fitness
  • IMCL (exploratory)
  • endothelial function (exploratory)
  • Coronary calcium score and stenosis (exploratory)
Not Provided
Not Provided
 
Lifestyle Modification and Metformin Use in the Treatment of HIV
Strategies for the Treatment of HIV Associated Metabolic Syndrome

A healthy diet and exercise have improved the health of people without human immunodeficiency virus (HIV) who have Metabolic Syndrome. In this study we would like to find out if the same benefit can be seen in people with HIV and Metabolic Syndrome. Patients with Metabolic Syndrome usually have a large waist, high blood cholesterol levels, high blood pressure, and high blood sugar levels. These are risk factors, which may increase one's chance of developing heart disease and/or diabetes. The purpose of the study is to evaluate the effects of different methods of treating HIV associated Metabolic Syndrome. The groups are: 1) a lifestyle modification program plus metformin (also known as glucophage), 2) lifestyle modification plus placebo, 3) metformin alone or 4) placebo alone. The lifestyle modification program consists of nutrition and exercise sessions with the goal of improving body composition, heart health, and ways to lower the risk of developing diabetes.

After two initial screening visits with medical and nutrition staff for informed consent and determination of eligibility qualifying subjects will be seen for a baseline visit.

At baseline subjects will have an interval history and physical exam, lipodystrophy evaluation by investigator and patient report. Bloods will be taken for insulin, glucose, HgbA1c, lipid studies, creatinine, liver function, serum lactate, urine pregnancy (women), CD4, viral load, and complete blood count (CBC). Metabolic assessment will include a 2-hour oral glucose tolerance test and indirect calorimetry. Carotid ultrasound will be done for assessment of intima-media thickness. Body composition will be assessed by dual energy x-ray absorptiometry (DEXA), single-slice magnetic resonance imaging (MRI) scanning through the abdomen and mid thigh, magnetic resonance spectroscopy scanning to assess intramyocellular lipid of the calf, anthropometric measurements, and Cardiac computed tomography (CT) will be done.

After the baseline visit, subjects will be randomized to 1 of 4 groups: 1) a lifestyle modification program plus metformin (also known as glucophage), 2) lifestyle modification plus placebo, 3) metformin alone or 4) placebo alone.

The starting dose of metformin will be 500mg twice daily and this will increase to 850mg twice daily at the 3-month visit.

An identical visit to that at baseline will be repeated at 12-months.

Subjects will return at 1 month for an interval history and physical exam, assessment of compliance and side effects. Blood will be collected for CBC, lactate, liver function, and creatinine. Women will have a urine pregnancy.

A 6-month visit will include an interval history and physical exam, assessment of compliance and side effects, 2 hour oral glucose tolerance test, fasting bloods (glucose, lipid panel, creatinine, liver function, serum lactate, CBC) will be done, a urine pregnancy will be checked in women. Carotid ultrasound will be done and body composition will be assessed by anthropometric measurements and DEXA scan.

There will also be a short visit at 3 and 9 months to obtain an interval history and physical exam, safety labs (serum lactate, CBC, liver function, and creatinine), urine pregnancy (women). Subjects randomized to metformin or placebo will increase their dose from 500mg twice daily to 850mg twice daily at the 3 month visit.

At each of the visits review of a 4 day food record will occur.

Those randomized to lifestyle modification will attend weekly sessions with a study investigator to cover a "core-curriculum" that is modeled after the Diabetes Prevention Program (DPP) intervention. The primary goals of the lifestyle modification program are derived from a combination of recommendations from the American Academy of Clinical Endocrinologists (AACE) and National Cholesterol Education Program (NCEP). The goals are to eat less than or equal to 35% of total calories from fat (less than 7% from saturated fat, up to 10% from polyunsaturated fat with emphasis on sources of omega 3 fatty acids and reduction of trans fatty acids, up to 20% from monounsaturated fats), and 25-35g of fiber per day.

The intensity of the counseling sessions will decrease in months 10 through 12 to biweekly counseling session with study investigators and biweekly phone contact, alternating.

In addition to the program outlined above, those randomized to the lifestyle modification group will also participate in progressive resistance training. Each training session will begin with a 5 minute warm-up on a stationary bicycle at 50% of the estimated maximal heart rate (maximal heart rate=220-age). All sessions will be monitored by a licensed physical therapist. Immediately after the warm-up, a standard flexibility routine will be performed to minimize the risk of injury. Then, the aerobic training protocol will be performed. The aerobic training program will follow the general guidelines established by the American College of Sports Medicine. Training will be performed using a standard stationary bicycle. Aerobic/endurance exercise will be performed with large muscle groups. Each subject will complete three supervised training sessions per week for 12 months.

Strength training will be performed using Keiser equipment. Selected muscle groups will be trained alternating upper and lower exercises in the following order: 1) hip extension, 2) lateral pull down, 3) knee extension, 4) elbow flexion, 5) knee flexion, and 6) chest press. Each repetition will include concentric and eccentric phases. Each muscle group will be trained individually 3 times per week, on alternate days. The subjects will perform three sets of 10 repetitions each for every muscle group, resting 2-3 seconds between repetitions, 2 minutes between sets, and 4 minutes between muscle groups. The 1 repetition maximum will be measured every 3-4 weeks for the first 6 months and it will be repeated again at the 9 and 12 month visits. The relative intensity will increase from 60-80% of the 1 repetition maximum over 6 months. Subjects not randomized to training will have a determination of 1 repetition maximum made at baseline, 6 and 12 months.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • HIV Infections
  • Metabolic Syndrome X
  • Drug: Metformin
    Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
  • Drug: Placebo
    500 mg twice daily increasing to 850 mg twice daily after 3 Months
  • Behavioral: Lifestyle Modification
    Lifestyle Modification
  • Placebo Comparator: Group 1
    No Lifestyle Modification and Placebo
    Intervention: Drug: Placebo
  • Active Comparator: Group 2
    Lifestyle Modification and Placebo
    Interventions:
    • Drug: Placebo
    • Behavioral: Lifestyle Modification
  • Active Comparator: Group 3
    No Lifestyle Modification and Metformin
    Intervention: Drug: Metformin
  • Active Comparator: Group 4
    Lifestyle Modification and Metformin
    Interventions:
    • Drug: Metformin
    • Behavioral: Lifestyle Modification
Fitch K, Abbara S, Lee H, Stavrou E, Sacks R, Michel T, Hemphill L, Torriani M, Grinspoon S. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS. 2012 Mar 13;26(5):587-97.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
June 2012
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age ≥ 18 and ≤ 65 years of age
  • HIV positive, on a stable combination antiretroviral regimen for > 6 months, including but not limited to either 2 nucleoside reverse transcriptase inhibitors (NRTI) and a non-nucleoside reverse transcriptase inhibitors (NNRTI) or protease inhibitor (PI), or a triple NRTI regimen
  • Ability and motivation to modify behavior and make lifestyle changes
  • NCEP-Adult Treatment Panel III defined metabolic syndrome, as defined by 3 out of 5 of the following: 1) Waist circumference greater than 102 cm (40 in) in men and 88 cm (35 in) in women, 2) Triglycerides ≥ 150 mg/dL or current anti-lipolytic drug treatment, 3) high-density lipoprotein less than 40mg/dL in men and 50 mg/dL in women, 4) Blood pressure ≥ 130/85 mmHg or current antihypertensive drug treatment, 5) Fasting glucose ≥ 100 mg/dL

Exclusion Criteria:

  • Any new serious opportunistic infection within the past 6 weeks
  • History of unstable angina, aortic stenosis, uncontrolled hypertension, severe neuropathy, arthritis or other contraindication to exercise
  • Current therapy with insulin or other diabetic agent, fasting blood sugar > 126
  • Requiring parenteral nutrition or parenteral glucocorticoid therapy or oral glucocorticoid therapy
  • Estrogen, progestational derivative, or ketoconazole use within 3 months
  • New antiretroviral regimen in the past 6 months
  • Serum creatinine > 1.5 mg/dL (males) and 1.4 mg/dL (females), serum glutamic pyruvic transaminase-liver function (SGPT), > 2.5 upper limit of normal (ULN), Lactate > 2.0 ULN, hemoglobin < 10.0 mg/dL
  • Current substance and/or alcohol abuse
  • Known hypersensitivity to Metformin
  • Congestive heart failure requiring pharmacologic treatment
  • Use of cimetidine or planned use during the study period
  • Hypertrophic obstructive cardiomyopathy
  • Pregnant or actively seeking pregnancy, breastfeeding
  • Testosterone use for non-physiologic purposes, or physiologic testosterone replacement for < 3 months.
  • Presence of active AIDS including cancers
  • Current viral, bacterial or other infections (excluding HIV)
  • Weight loss in the past 3 months of greater than 10 pounds
  • Nitrates or other medications that can alter endothelial function
  • Contraindication to beta blocker or nitroglycerin use
  • Patients with previous allergic reactions to iodine-containing contrast media or to iodine
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00399360
DK-49302-10AR, R01DK049302
Yes
Steven K. Grinspoon, MD, Massachusetts General Hospital
Massachusetts General Hospital
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Steven K. Grinspoon, MD Massachusetts General Hospital
Massachusetts General Hospital
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP